Hims & Hers Health, Inc.
- Open
- 28.67
- Day high
- 29.79
- Day low
- 28.64
- Prev close
- 28.84
- Volume
- 8.2M
- Mkt cap
- $6.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 21.3
- P/S
- 2.7
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$7.2M over the last 3 months (0 open-market buys, 13 sales)
- 🏛Institutions accumulating (13F)
Hims & Hers Health, Inc. (HIMS) is a Healthcare company listed on NYSE. The stock is down 29% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 13 sales (SEC Form 4).
Hims & Hers Health, Inc. (HIMS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 9 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
HIMS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.05 | $-0.37 | -643.1% | $753M | +7.8% |
| May 11, 2026 | $0.04 | $-0.18 | -550.0% | $608M | -1.4% |
| Feb 23, 2026 | $0.02 | $0.08 | +315.2% | $618M | +0.1% |
| Feb 27, 2023 | $-0.07 | $-0.05 | +28.6% | $167M | +3.7% |
| Feb 22, 2022 | $-0.10 | $-0.11 | -10.0% | $85M | +10.7% |
| Nov 10, 2021 | $-0.14 | $-0.09 | +35.7% | $74M | -26.3% |
| Aug 11, 2021 | $-0.16 | $-0.08 | +50.0% | $61M | +6.6% |
| May 17, 2021 | $-0.15 | $-0.14 | +6.7% | $52M | +0.0% |
| Mar 18, 2021 | $-0.36 | $-0.07 | +80.6% | $41M | — |
| Aug 13, 2020 | — | $-0.03 | — | $36M | — |
| May 13, 2020 | — | $-0.17 | — | $30M | — |
| Mar 27, 2020 | — | $-0.36 | — | $25M | — |
HIMS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 20, 2026 | Boughton Soleilofficer: Chief Legal Officer | Sell | 25,111 | $27.55 |
| Aug 20, 2026 | Okupe Oluyemiofficer: Chief Financial Officer | Sell | 4,938 | $29.99 |
| Aug 20, 2026 | Autor Deborah M.director, officer: Chief Policy Officer | Sell | 16,773 | $27.85 |
| Aug 20, 2026 | Okupe Oluyemiofficer: Chief Financial Officer | Option | 4,938 | $5.01 |
| Aug 18, 2026 | Okupe Oluyemiofficer: Chief Financial Officer | Option | 71,616 | — |
| Aug 18, 2026 | Chi Michaelofficer: Chief Operating Officer | Option | 19,358 | — |
| Aug 18, 2026 | Boughton Soleilofficer: Chief Legal Officer | Option | 12,099 | — |
| Aug 18, 2026 | Becklund Ireneofficer: PAO | Option | 3,880 | — |
| Aug 18, 2026 | Boughton Soleilofficer: Chief Legal Officer | Tax | 21,500 | $28.15 |
| Aug 18, 2026 | Autor Deborah M.director, officer: Chief Policy Officer | Option | 32,920 | — |
| Aug 18, 2026 | Boughton Soleilofficer: Chief Legal Officer | Option | 12,223 | — |
| Aug 18, 2026 | Okupe Oluyemiofficer: Chief Financial Officer | Sell | 55,383 | $35.09 |
| Aug 18, 2026 | Becklund Ireneofficer: PAO | Option | 4,345 | — |
| Aug 18, 2026 | Okupe Oluyemiofficer: Chief Financial Officer | Tax | 36,437 | $28.15 |
| Aug 18, 2026 | Chi Michaelofficer: Chief Operating Officer | Option | 10,600 | — |
Source: HIMS SEC Form 4 filings, latest Aug 20, 2026. For informational purposes only — not investment advice.
See the full HIMS insider & 13F page →Hims & Hers Health, Inc. company profile
Overview
Hims & Hers Health, Inc. (NYSE:HIMS) is a San Francisco-based telehealth company that operates a multi-specialty digital health platform connecting consumers directly to licensed healthcare professionals. Founded in 2017, the company went public in 2019 and has rapidly expanded from its initial focus on men's sexual health to become a comprehensive telehealth provider serving over 2.4 million subscribers across multiple health specialties including weight management, dermatology, mental health, and sexual wellness.
Business
Hims & Hers operates in the telehealth and direct-to-consumer healthcare industry, which represents a digital transformation of traditional healthcare delivery. The company's core offering is a technology-enabled platform that allows patients to consult with licensed healthcare providers remotely, receive personalized treatment plans, and have prescription medications delivered directly to their homes. The telehealth industry emerged as an alternative to traditional in-person medical visits, particularly for conditions that don't require physical examination or for ongoing care management. Patients access services through the company's websites and mobile applications, complete health assessments, and connect with healthcare providers via video consultations or messaging platforms. Hims & Hers focuses on five primary health specialties that generate the majority of its revenue: 1. Weight Management - The company's fastest-growing segment, offering GLP-1 medications (like semaglutide), oral weight loss treatments, and personalized weight management programs. This specialty contributed over $225 million in revenue during 2024 and represents approximately 15% of total revenue. 2. Sexual Health and Wellness - The original focus area covering treatments for erectile dysfunction, premature ejaculation, and other sexual health concerns for both men and women, representing roughly 25-30% of revenue. 3. Dermatology - Skincare treatments including acne management, anti-aging solutions, and prescription dermatological medications, accounting for approximately 20-25% of revenue. 4. Hair Care - Treatments for hair loss including minoxidil, finasteride, and other hair restoration solutions, representing about 15-20% of revenue. 5. Mental Health - Anxiety, depression, and other mental health treatments through licensed providers, comprising roughly 10-15% of revenue. The company also offers over-the-counter products including vitamins, supplements, skincare products, and wellness items that complement its prescription offerings.
Revenue model
Hims & Hers generates revenue through multiple interconnected business models centered around subscription-based healthcare services. The primary revenue stream comes from monthly subscription fees paid by patients for ongoing access to healthcare providers and prescription medications. The average monthly revenue per subscriber has grown to $84, reflecting the company's shift toward higher-value, personalized treatments. The company's paying customers are primarily individual consumers who pay out-of-pocket for services, as most treatments offered are not covered by traditional health insurance. This cash-pay model allows Hims & Hers to offer transparent pricing and avoid the complexities of insurance reimbursement, though it limits the addressable market to consumers willing and able to pay directly. Revenue generation occurs through several channels: 1. Subscription fees for ongoing care and medication refills, 2. Product sales of both prescription and over-the-counter items, 3. Consultation fees for initial and follow-up medical consultations, and 4. Wholesale partnerships with retail pharmacies and other healthcare providers. Several factors influence the company's margins and profitability. Positive margin drivers include the scalability of the technology platform, vertical integration through owned pharmacy facilities, increasing adoption of higher-margin personalized treatments (over 55% of subscribers now use personalized solutions), and operational efficiencies from automation. The company has achieved gross margins around 79%. Margin pressures come from increased competition in telehealth, potential regulatory changes affecting telemedicine or specific medications, supply chain disruptions for key medications (particularly GLP-1 drugs), customer acquisition costs in digital marketing channels, and the need for continued investment in clinical infrastructure and technology development. The company also faces margin compression when launching new specialties that initially require higher marketing spend and operational setup costs.
Competitive moat
Hims & Hers possesses a moderate but growing competitive moat built primarily around network effects, data advantages, and operational scale. The company's strongest defensive position comes from its integrated technology platform that combines patient acquisition, clinical care delivery, pharmacy operations, and fulfillment in a single ecosystem. This vertical integration creates operational efficiencies and customer experience advantages that are difficult for competitors to replicate quickly. The company's data and personalization capabilities represent an emerging moat. With over 2.4 million subscribers and millions of patient interactions, Hims & Hers has built proprietary datasets that inform its AI-powered MedMatch technology for personalized treatment recommendations. This data advantage compounds over time, enabling better patient outcomes and retention rates that competitors cannot easily match. Brand recognition and trust in healthcare create meaningful barriers to entry. The company has invested heavily in building consumer trust through clinical excellence, transparent pricing, and consistent service delivery. Healthcare consumers tend to be sticky once they find a provider they trust, particularly for sensitive conditions like sexual health or mental wellness. However, the moat faces significant competitive threats. Large technology companies like Amazon (with Amazon Pharmacy and One Medical), traditional healthcare systems expanding into telehealth, and well-funded competitors like Ro and Nurx are all competing for similar patient populations. The regulatory environment around telehealth and specific medications (particularly controlled substances and compounded drugs) could change in ways that favor larger, more established healthcare providers. The company's reliance on cash-pay customers also limits its moat, as competitors offering insurance-covered services could potentially capture market share. Additionally, as telehealth becomes more commoditized, differentiation may become increasingly difficult to maintain without continuous innovation and investment.
Risks & safety
Hims & Hers demonstrates a strong financial safety profile with improving profitability metrics and solid balance sheet fundamentals. • Liquidity and Cash Position: $274 million in cash and short-term investments with positive operating cash flow of $109 million in Q1 2025, indicating strong cash generation capabilities • Debt and Solvency: Very low debt-to-equity ratio of 0.12, minimal solvency risk with current ratio of 1.59 and quick ratio of 1.32 • Profitability Trends: Achieved adjusted EBITDA of $91 million in Q1 2025 (nearly tripled year-over-year), with positive net income of $49 million and strong free cash flow of $54 million • Valuation Metrics: Trading at 33x P/E ratio and 24x EV/EBITDA, which appears reasonable given 111% revenue growth rate and improving profitability trajectory • Growth Sustainability: Revenue guidance of $2.3-2.4 billion for 2025 represents continued strong growth, with management targeting $6.5 billion revenue by 2030 • Other Considerations: Regulatory risks around telehealth and compounded medications, dependence on cash-pay model, and competitive pressures in the telehealth space
Recent development
Over the past few years, Hims & Hers has executed a significant strategic transformation from a single-specialty men's health company to a comprehensive multi-specialty telehealth platform. The most notable development has been the rapid expansion into weight management, which became the company's fastest-growing specialty after launching GLP-1 treatments in 2024. This specialty alone generated over $225 million in revenue during 2024, reaching a $100 million annual run rate within just seven months of launch. The company has aggressively pursued vertical integration to improve margins and control quality. Key acquisitions include a whole-body lab testing provider, an FDA-registered 503(b) peptide facility in California, and investments in sterile compounding capabilities. These moves enable Hims & Hers to offer personalized medications and diagnostic services while reducing dependence on third-party suppliers. Personalization has emerged as a core differentiator, with over 55% of subscribers now using personalized treatment solutions compared to standard protocols. The company has developed proprietary AI-powered technology called MedMatch that uses patient data to recommend optimal treatment approaches, leading to improved outcomes and higher revenue per subscriber. Strategic partnerships have become increasingly important, particularly the collaboration with Novo Nordisk to expand weight loss treatment options. The company has also broadened its retail presence through partnerships with CVS, Walgreens, and Walmart, while maintaining its direct-to-consumer focus. Recent organizational changes include hiring Nader Kabbani as Chief Operating Officer and Dr. Jessica Shepherd as Chief Medical Officer of Hers, reflecting the company's commitment to operational excellence and clinical leadership as it scales.
HIMS company profile · for informational purposes only — not investment advice.
Track HIMS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free